

Table SI. Association of EMP3 expression with clinicopathological indicators and patient outcomes (n=166).

Indicator	EMP3 expression (%)				P-value
	- (n=64)	+ (n=30)	++ (n=13)	+++ (n=59)	
Stage					0.836
I	12 (19)	5 (17)	1 (8)	14 (24)	
II	37 (58)	20 (66)	10 (77)	33 (56)	
III	15 (23)	5 (17)	2 (15)	12 (20)	
pT status					0.493
1	20 (31)	7 (23)	1 (8)	20 (34)	
2	39 (61)	22 (73)	11 (84)	35 (59)	
3/4	5 (8)	1 (4)	1 (8)	4 (7)	
Nodal status					0.180
Negative	30 (47)	18 (60)	8 (62)	39 (66)	
Positive	34 (53)	12 (40)	5 (38)	20 (34)	
ER status					0.713
Negative	20 (31)	8 (27)	3 (23)	13 (22)	
Positive	44 (69)	22 (73)	10 (77)	46 (78)	
PR status					0.608
Negative	35 (55)	12 (40)	6 (46)	29 (49)	
Positive	29 (45)	18 (60)	7 (54)	30 (51)	
HER2					0.192
Not amplified	50 (78)	19 (63)	12 (92)	42 (71)	
Amplified	14 (22)	11 (37)	1 (8)	17 (29)	
Recurrence					0.853
Negative	54 (84)	24 (80)	10 (77)	47 (80)	
Positive	10 (16)	6 (20)	3 (23)	12 (20)	
Survival status					0.593
Alive	51 (80)	27 (90)	10 (77)	48 (81)	
Deceased	13 (20)	3 (10)	3 (23)	11 (19)	

EMP, epithelial membrane protein; pT, pathological primary tumor; ER, estrogen receptor; PR, progesterone receptor; HER, human epidermal growth factor receptor